Rupali Verma, the lead analyst, said, "Most of the non-tyrosine kinase
inhibitors being developed target mTOR, CDK, RAF and MEK kinases
The Non-Tyrosine Kinase
Inhibitors in Oncology, 2015-2025 report provides a comprehensive analysis of the current market landscape and the future outlook of kinase
inhibitors not specifically targeting tyrosine kinases
Carver College of Medicine, said: "CaM kinase
helps regulate calcium, which is essential to heart function, but CaM kinase
's calcium connection also can play a role in electrical problems that lead to irregular heart beats and cell death.
Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase
-1 (PLK1) was identified as the principal protein kinase
that carried out B23 phosphorylation at this site, and these findings point to PLK1 as a very promising cancer drug target.
Overexpression of ERK, an EPH family receptor protein tyrosine kinase
, in various human tumors.
levels, protein kinase
activation, and the functional consequences of these changes on the target macrophage.
The oral drug, also known as STI-571, works by binding to Bcr-Abl tyrosine kinase
on CML cells, thereby disabling them.
Co-senior author Patrick Zarrinkar notes: "this study reveals that for a majority of the primary, intended kinase
targets of the inhibitors tested, at least one selective compound has been identified, and we are thus optimistic that a majority of kinases
can be targeted by selective inhibitors".
Small molecule protein kinase
inhibitors are a type of targeted therapy that involves small molecule drugs administered in the cancer patient for specifically targeting certain proteins, called kinases
, involved in the growth of cancer cells.
) has announced the addition of the "Tyrosine Kinase
Inhibitors Market & Pipeline Insight 2015" report to their offering.
com)-- Stephan Grant, Senior Director of Oncology Research Unit and Head of Biochemistry & Primary Screening, will give a featured presentation on “Critical Influences on Kinase
Inhibitor Binding From Outside the ATP Binding Site” at the 2nd Protein Kinases
& Drug Design Conference to be held in San Diego, CA on October 23-25, 2013 by GTC.
Researchers with US and European drug companies share insights into growth factor inhibitors VEDFR2, ERBB2, and other kinases
; MEK inhibitors; the cell cycle kinase
inhibitors Aurora kinase
and PLK inhibitors; and related topics.
Blocking of the extracellular signal-regulated protein kinase
pathway with U0126 or inhibition of p38 activity with SB203580 did not suppress chrysotile-induced Ser15 phosphorylation.
Details of this region are critical for the design of compounds that specifically target the kinase
and form an essential part of Keryx's KinAce bioinformatics technology platform that utilizes sequence based genomics data for drug discovery.